Premium
Intravenous ketamine in status epilepticus
Author(s) -
Höfler Julia,
Trinka Eugen
Publication year - 2018
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.14480
Subject(s) - status epilepticus , ketamine , medicine , prospective cohort study , refractory (planetary science) , adverse effect , retrospective cohort study , pediatrics , nmda receptor , anesthesia , psychiatry , epilepsy , receptor , biology , astrobiology
Summary Status epilepticus ( SE ) is among the most common neurological emergencies. In refractory SE , due to subcellular maladaptive changes, γ‐aminobutyric acidergic drugs are no longer effective, and there is an increase in synaptic N ‐methyl‐ d ‐aspartate ( NMDA ) receptors. Ketamine ( KET ) is a noncompetitive N ‐methyl‐ d ‐aspartate receptor antagonist that could be of value in the treatment of refractory SE . The aim was to analyze all published studies on KET in the treatment of SE . A systematic search (PubMed) of the literature identified 25 studies (from December 1996 to March 2017); with the exception of two prospective studies, all studies were retrospective in nature and published as a full paper. To date, PubMed lists a total number of 244 episodes of SE treated with KET (13 case reports and five case series in adults; four case reports and three case series in children); the overall success rate was 74% (153/207) in adults and 73% (27/37) in children. Adverse events were rare. Current evidence on the use of KET in acute seizures and SE is mostly restricted to retrospective case reports and case series, except for two prospective case series without control (class IV ). Further prospective studies to inform clinicians are necessary.